Letaplimab represents a unique medical strategy for addressing complement-mediated illnesses. This antibody targets the C1q protein, a essential component of the complement system, aiming to inhibit its first https://theopsxq692087.blognody.com/49499020/letaplimab-a-new-medical-strategy